The risk of adverse effects associated with cholesterol lowering drugs used for the prevention of heart disease or stroke is not common according to the latest research published in the circulation Cardiovascular Quality and Outcomes.
During this study researchers tracked the data of 135 previous drug related studies to determine the safety and efficacy of seven statins available in the market. The authors suggested that station as a class does not cause common adverse effects.
There were two generic named as simvastatin (Zocor) and pravastatin (Pravachol) that have shown best safety profiles when started from low dose to high dose as said by said Huseyin Naci, M.H.S., the study’s lead author and a doctoral candidate at the London School of Economics and Political Science and research fellow at Harvard Medical School’s Department of Population Medicine.
The risk of diabetes was 9% more in patient using statins. “I am concerned that patients may misunderstand this small increase in risk and stop adhering to their medications,” Naci said.
The proven ability of statins to significantly cut the rate of death and hospitalization in patients who have heart disease outweighs the “small increase in diabetes risk,” he said.
Table: 1 Tabulated data showing different different aspects of this research work.
|Research studies||Number of Patients||Time Period||Duration of each Trial|
|135||250,000||1985-2013||More than one year|
During all these studies researchers compared one statin with other or stating with the placebo. The conclusion given authors at the end of this study was as follows;
“As a class, adverse events associated with statin therapy are not common. Statins are not associated with cancer risk but do result in a higher odds of diabetes mellitus. Among individual statins, simvastatin and pravastatin seem safer and more tolerable than other statins.”